- Home
- NXTC vs NXN Comparison
NXTC vs NXN Comparison
Compare NXTC & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXTC | NXN |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 47.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | NXTC | NXN |
|---|---|---|
| Price | $13.37 | $12.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 34.5K | 9.7K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $48.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $10.64 |
| 52 Week High | $15.74 | $12.45 |
Technical Indicators
Market Signals| Indicator | NXTC | NXN |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 54.91 |
| Support Level | $12.99 | $12.03 |
| Resistance Level | $13.98 | $12.17 |
| Average True Range (ATR) | 1.00 | 0.09 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 67.65 | 81.82 |
Price Performance
Historical ComparisonAbout NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.